Featured Research

from universities, journals, and other organizations

New route for development of anti-diarrhea drugs

Date:
December 10, 2013
Source:
Royal College of Surgeons in Ireland (RCSI)
Summary:
New gastroenterology research has uncovered a new route for the development of anti-diarrhea drugs. The new route directly targets cells and molecular processes that control water movement into the intestine and may help with the development of a new class of anti-diarrhea medication.

New gastroenterology research carried out by the RCSI (Royal College of Surgeons in Ireland) in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhea drugs. The new route directly targets cells and molecular processes that control water movement into the intestine and may help with the development of a new class of anti-diarrhea medication.

The research found that drugs which act on a protein called Farnesoid X Receptor (FXR) in the tissue of the intestine can stop water moving in to the gut. By switching off the water movement in to the gut, this can prevent diarrhea occurring.

Dr Stephen Keely, Associate Director of Molecular Medicine, RCSI and lead researcher, said 'diarrhea diseases are common and debilitating but safe and effective drugs for their treatment are still lacking. Our research has found that FXR is an important regulator of intestinal function and has excellent potential for the development of a new class of anti-diarrhea drugs."

In Ireland, diarrhea is the main reason for approximately 40,000 visits to gastroenterology clinics annually. Epidemics of acute infectious diarrhea are common, and many illnesses such as inflammatory bowel disease, digestive disorders and irritable bowel syndrome cause disruptions to the normal functioning of the intestine and lead to diarrhea. These conditions have a large financial burden to society both in terms of healthcare and lost hours of work.

The research found that drugs which target the FXR protein, target the cells lining the intestine, and because of this they may have broader efficacy and fewer side effects than many anti-diarrheas currently available on the market.

The research was published in Gut, an international journal in gastroenterology.


Story Source:

The above story is based on materials provided by Royal College of Surgeons in Ireland (RCSI). Note: Materials may be edited for content and length.


Journal Reference:

  1. M. S. Mroz, N. Keating, J. B. Ward, R. Sarker, S. Amu, G. Aviello, M. Donowitz, P. G. Fallon, S. J. Keely. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut, 2013; DOI: 10.1136/gutjnl-2013-305088

Cite This Page:

Royal College of Surgeons in Ireland (RCSI). "New route for development of anti-diarrhea drugs." ScienceDaily. ScienceDaily, 10 December 2013. <www.sciencedaily.com/releases/2013/12/131210091240.htm>.
Royal College of Surgeons in Ireland (RCSI). (2013, December 10). New route for development of anti-diarrhea drugs. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2013/12/131210091240.htm
Royal College of Surgeons in Ireland (RCSI). "New route for development of anti-diarrhea drugs." ScienceDaily. www.sciencedaily.com/releases/2013/12/131210091240.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins